Champions Oncology Shares Jump After Swinging to Profit, Posting Higher Revenue in 1Q

Dow Jones09-12

By Connor Hart

Shares of Champions Oncology surged after the company swung to a profit and posted higher revenue in its fiscal first quarter.

The stock rose 30% to $5.30 in after-hours trading Wednesday. Shares ended the regular session up 3% to $4.07, putting them down 28% since the beginning of the year.

The Hackensack, N.J., biotechnology company, which provides end-to-end oncology solutions, posted net income of $1.3 million, or 9 cents a share, for its three months ended July 31, compared with a loss of $2.6 million, or 19 cents a share, in last year's quarter.

Adjusted per-share earnings were 11 cents.

Revenue rose 12% to $14.1 million, boosted by operational improvements and efficiencies that led to an increase in bookings-to-revenue conversion percentage.

Chief Executive Ronnie Morris said, "we're cautiously optimistic that we've weathered the worst of the business downturn, and we're poised to emerge leaner and stronger."

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

September 11, 2024 17:30 ET (21:30 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466265327?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-12 05:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466265327","market":"other","top_or_hot":-1,"title":"Champions Oncology Shares Jump After Swinging to Profit, Posting Higher Revenue in 1Q","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Champions Oncology surged after the company swung to a profit and posted higher revenue in its fiscal first quarter. \n</p>\n<p>\n  The stock rose 30% to $5.30 in after-hours trading Wednesday. Shares ended the regular session up 3% to $4.07, putting them down 28% since the beginning of the year. \n</p>\n<p>\n  The Hackensack, N.J., biotechnology company, which provides end-to-end oncology solutions, posted net income of $1.3 million, or 9 cents a share, for its three months ended July 31, compared with a loss of $2.6 million, or 19 cents a share, in last year's quarter. \n</p>\n<p>\n  Adjusted per-share earnings were 11 cents. \n</p>\n<p>\n  Revenue rose 12% to $14.1 million, boosted by operational improvements and efficiencies that led to an increase in bookings-to-revenue conversion percentage. \n</p>\n<p>\n  Chief Executive Ronnie Morris said, \"we're cautiously optimistic that we've weathered the worst of the business downturn, and we're poised to emerge leaner and stronger.\" \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 11, 2024 17:30 ET (21:30 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Champions Oncology Shares Jump After Swinging to Profit, Posting Higher Revenue in 1Q</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChampions Oncology Shares Jump After Swinging to Profit, Posting Higher Revenue in 1Q\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-12 05:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Connor Hart \n\n\n \n\n\n  Shares of Champions Oncology surged after the company swung to a profit and posted higher revenue in its fiscal first quarter. \n\n\n  The stock rose 30% to $5.30 in after-hours ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSBR","symbol_name":"Champions Oncology, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2466265327","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466265327","pubTimestamp":1726090200,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Champions Oncology surged after the company swung to a profit and posted higher revenue in its fiscal first quarter.The stock rose 30% to $5.30 in after-hours trading Wednesday. Shares ended the regular session up 3% to $4.07, putting them down 28% since the beginning of the year.The Hackensack, N.J., biotechnology company, which provides end-to-end oncology solutions, posted net income of $1.3 million, or 9 cents a share, for its three months ended July 31, compared with a loss of $2.6 million, or 19 cents a share, in last year's quarter.Revenue rose 12% to $14.1 million, boosted by operational improvements and efficiencies that led to an increase in bookings-to-revenue conversion percentage.Chief Executive Ronnie Morris said, \"we're cautiously optimistic that we've weathered the worst of the business downturn, and we're poised to emerge leaner and stronger.\"","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CSBR":"Champions Oncology, Inc."},"translate_title":"Champions Oncology股价在扭亏为盈后上涨，第一季度收入增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSBR":1},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Champions Oncology surged after the company swung to a profit and posted higher revenue in its fiscal first quarter. \n\n\n  The stock rose 30% to $5.30 in after-hours trading Wednesday. Shares ended the regular session up 3% to $4.07, putting them down 28% since the beginning of the year. \n\n\n  The Hackensack, N.J., biotechnology company, which provides end-to-end oncology solutions, posted net income of $1.3 million, or 9 cents a share, for its three months ended July 31, compared with a loss of $2.6 million, or 19 cents a share, in last year's quarter. \n\n\n  Adjusted per-share earnings were 11 cents. \n\n\n  Revenue rose 12% to $14.1 million, boosted by operational improvements and efficiencies that led to an increase in bookings-to-revenue conversion percentage. \n\n\n  Chief Executive Ronnie Morris said, \"we're cautiously optimistic that we've weathered the worst of the business downturn, and we're poised to emerge leaner and stronger.\" \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 11, 2024 17:30 ET (21:30 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466265327"}